Comparing Inhibitor Therapeutics (OTCMKTS:INTI) & InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX) and Inhibitor Therapeutics (OTCMKTS:INTI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Profitability

This table compares InflaRx and Inhibitor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InflaRx	-33,362.70%	-65.98%	-56.86%
Inhibitor Therapeutics	N/A	-70.65%	-40.64%

Valuation & Earnings

This table compares InflaRx and Inhibitor Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$129,752.00	439.79	-$46.18 million	($0.82)	-1.04
Inhibitor Therapeutics	N/A	N/A	-$3.03 million	($0.01)	-5.40

Inhibitor Therapeutics has lower revenue, but higher earnings than InflaRx. Inhibitor Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for InflaRx and Inhibitor Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	0	0	5	0	3.00
Inhibitor Therapeutics	0	0	0	0	0.00

InflaRx presently has a consensus price target of $6.60, suggesting a potential upside of 676.47%. Given InflaRx’s stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than Inhibitor Therapeutics.

Volatility and Risk

InflaRx has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Inhibitor Therapeutics has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500.

Institutional & Insider Ownership

42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 4.6% of Inhibitor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

InflaRx beats Inhibitor Therapeutics on 9 of the 13 factors compared between the two stocks.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.